+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhaled nitric oxide in primary pulmonary hypertension The Perfect pulmonary vasodilator



Inhaled nitric oxide in primary pulmonary hypertension The Perfect pulmonary vasodilator



Circulation 92(8 Suppl. ): I241




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031940085

Download citation: RISBibTeXText


Related references

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 100(18 Suppl. ): I 240, Nov 2, 1999

Inhaled nitric oxide a selective pulmonary vasodilator for the treatment of persistent pulmonary hypertension of the newborn pphn. Circulation 84(4 Suppl. 2): II321, 1991

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2005

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. American Journal of Respiratory and Critical Care Medicine 151(2 Pt 1): 384-389, 1995

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Phosphodiesterase inhibition with dipyridamole augments and prolongs the pulmonary vasodilator response to inhaled nitric oxide in adults with chronic pulmonary hypertension. Circulation 98(17 Suppl. ): I614, Oct 27, 1998

Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. American Journal of Cardiology 77(7): 532-535, 1996

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110(15): 2253-2259, 2004

The response to inhaled nitric oxide in adult patients with primary pulmonary hypertension and pulmonary hypertension from secondary causes. Journal of the American College of Cardiology 35(2 Suppl A): 286A, 2000

Vasodilator response to inhaled nitric oxide is the most powerful predictor of survival in patients with pulmonary hypertension. Circulation 108(17 Suppl.): IV-561, October 28, 2003

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. American Heart Journal 150(4): 725-728, 2005

Inhaled nitric oxide a selective vasodilator for the treatment of pulmonary artery hypertension in congenital heart disease. Pediatric Research 31(4 Part 2): 20A, 1992

Selective pulmonary vasodilator effect of inhaled nitric oxide in a patient with pulmonary thromboembolism. Medicina Clinica 105(7): 261-263, 1995